Skip to main content
An official website of the United States government
Español
Email

Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version

Childhood Benign Breast Tumors (Fibroadenoma and Phyllodes)

Go to Patient Version

Incidence and Risk Factors

Benign fibroadenomas are the most common breast tumors seen in children aged 18 years or younger.[1,2] The prevalence of fibroadenoma is 2.2% in females aged 10 to 30 years.[1,2] The incidence increases with age, although girls aged 12 to 16 years tend to have larger lesions than women aged 17 years and older.[3] More than 95% of patients are female. Types of fibroadenoma in children aged 18 years or younger include simple fibroadenoma (70%–90% of cases) and giant juvenile fibroadenoma (0.5%–2% of cases).[2]

Fibroadenomas have been associated with Beckwith-Wiedemann, Maffucci, and Cowden syndromes.[2]

Other benign breast masses include tubular adenomas, benign phyllodes tumors, and benign fibroepithelial neoplasms.[4]

Clinical Presentation

Fibroadenoma usually presents as an asymptomatic mass that can vary in size with a woman's menstrual cycle. They can cause localized pain or breast asymmetry. They can also be associated with skin ulceration and venous engorgement.[2,4]

Giant juvenile fibroadenomas have been variably defined as any rapidly enlarging encapsulated fibroadenoma with a diameter greater than 5 cm, a weight more than 500 g, or displacement of at least four-fifths of the breast.[2,4]

In one retrospective series of 80 girls aged 12 to 18 years with fibroadenomas, 10% of patients had bilateral disease, and 2.5% of patients had unilateral disease but more than one nodule (multicentric fibroadenoma).[3]

Diagnosis

Fibroadenomas are benign biphasic tumors with epithelial and stromal components that have variable mitotic activity.[3] These tumors can be difficult to distinguish from phyllodes tumors when a tumor sample is obtained using fine needle aspiration or core needle biopsy.

Fine needle aspiration is not considered to be adequate for diagnosis. Indications for core needle biopsy or excision of a suspected fibroadenoma in children and adolescents are not based on evidence. The indications include tumor size at presentation of 2 cm to 5 cm (or larger), tumor enlargement during 2 to 12 months of observation, and multiple breast masses or bilateral breast masses.[2,5]

One single-institution retrospective review conducted between 1999 and 2018 aimed to characterize the breast masses of 70 females aged 19 years or younger with fibroadenomas who underwent excision of masses between 2 cm and 16 cm. Histological evaluation found that 87% of the breast masses were benign, 10% of the masses were benign phyllodes tumors that were aggressive in nature (n = 7), one mass was a malignant phyllodes tumor, and one mass was a metastatic sarcoma.[5]

Pathological examination of the core needle biopsy specimen may underestimate or overestimate the aggressiveness of lesions when compared with what is found on excision in about 13% of patients.[5]

Another single-institution retrospective analysis performed genomic profiling on 44 fibroadenomas and 36 giant fibroadenomas.[6] The giant fibroadenomas were biologically distinct from fibroadenomas of the breast, with overexpression of genes involved in the regulation of cell growth and immune response.

Treatment of Fibroadenoma and Phyllodes Tumors

Treatment options for fibroadenoma include the following:

  1. Observation.
  2. Surgery.

Observation

Evidence (observation):

  1. A study of 29 patients with presumed fibroadenomas were diagnosed prospectively over a 13-month period via physical examination.[7]
    • Nine presumed fibroadenomas (31%) resolved during the follow-up period of 1 to 12 months, and four presumed fibroadenomas (14%) became smaller.
    • Twelve teenagers underwent ultrasonography and had solid masses. None of these masses resolved after a year of observation. In addition, resection determined that all of these masses were fibroadenomas.

There is no evidence that childhood or adolescent fibroadenomas have carcinomatous potential.

Surgery

Indications for resection include tumor size at presentation of 2 cm to 5 cm (or larger); tumor enlargement during 2 to 12 months of observation; multiple breast masses or bilateral breast masses; and patient, parental, or provider anxiety.[1,2]

Evidence (surgery):

  1. In one series of 39 patients with fibroadenomas who had follow-up after resection, the following was observed:[3]
    • Six patients experienced recurrences between 2 years and 7.5 years (median, 4.9 years) later.
    • Tumor size, mitotic index, and mesenchymal cellularity did not predict recurrences, and all recurrent tumors were benign.

Surgical complications have included breast hypoplasia, acute pain, and chronic pain.[8]

While recurrence is rare, careful follow-up monitoring is important. Recurrent tumors can be resected successfully using conservative techniques.[8]

Treatment options for phyllodes tumors include the following:

  1. Surgery.

Surgery (wide local excision without mastectomy)

Phyllodes tumors can be very large and challenging to treat surgically in women with smaller breasts. Complete excision of the phyllodes tumor with grossly negative margins and a small amount of normal tissue circumferentially is necessary. Radical mastectomy or modified radical mastectomy should be avoided. Lymph node evaluation is not necessary.[9]

Phyllodes tumors present a small risk of recurrence, as they fall into the intermediate-grade sarcoma category. These tumors do not metastasize, but they can recur locally.

References
  1. Jayasinghe Y, Simmons PS: Fibroadenomas in adolescence. Curr Opin Obstet Gynecol 21 (5): 402-6, 2009. [PUBMED Abstract]
  2. Lee M, Soltanian HT: Breast fibroadenomas in adolescents: current perspectives. Adolesc Health Med Ther 6: 159-63, 2015. [PUBMED Abstract]
  3. Sun C, Zhang W, Ma H, et al.: Main Traits of Breast Fibroadenoma Among Adolescent Girls. Cancer Biother Radiopharm 35 (4): 271-276, 2020. [PUBMED Abstract]
  4. McLaughlin CM, Gonzalez-Hernandez J, Bennett M, et al.: Pediatric breast masses: an argument for observation. J Surg Res 228: 247-252, 2018. [PUBMED Abstract]
  5. Zmora O, Klin B, Iacob C, et al.: Characterizing excised breast masses in children and adolescents-Can a more aggressive pathology be predicted? J Pediatr Surg 55 (10): 2197-2200, 2020. [PUBMED Abstract]
  6. Yin Lee JP, Thomas AJ, Lum SK, et al.: Gene expression profiling of giant fibroadenomas of the breast. Surg Oncol 37: 101536, 2021. [PUBMED Abstract]
  7. Neinstein LS, Atkinson J, Diament M: Prevalence and longitudinal study of breast masses in adolescents. J Adolesc Health 14 (4): 277-81, 1993. [PUBMED Abstract]
  8. Javed A, Jenkins SM, Labow B, et al.: Intermediate and long-term outcomes of fibroadenoma excision in adolescent and young adult patients. Breast J 25 (1): 91-95, 2019. [PUBMED Abstract]
  9. Valdes EK, Boolbol SK, Cohen JM, et al.: Malignant transformation of a breast fibroadenoma to cystosarcoma phyllodes: case report and review of the literature. Am Surg 71 (4): 348-53, 2005. [PUBMED Abstract]

Special Considerations for the Treatment of Children With Cancer

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

  • Primary care physicians.
  • Pediatric surgeons.
  • Pathologists.
  • Pediatric radiation oncologists.
  • Pediatric medical oncologists and hematologists.
  • Ophthalmologists.
  • Rehabilitation specialists.
  • Pediatric oncology nurses.
  • Social workers.
  • Child-life professionals.
  • Psychologists.
  • Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

  • A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]
  • The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4]

    Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Breast Cancer Treatment.

References
  1. Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010. [PUBMED Abstract]
  2. American Academy of Pediatrics: Standards for pediatric cancer centers. Pediatrics 134 (2): 410-4, 2014. Also available online. Last accessed August 23, 2024.
  3. Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014. [PUBMED Abstract]
  4. National Cancer Institute: NCCR*Explorer: An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. Available online. Last accessed August 23, 2024.
  5. Surveillance Research Program, National Cancer Institute: SEER*Explorer: An interactive website for SEER cancer statistics. Bethesda, MD: National Cancer Institute. Available online. Last accessed September 5, 2024.
  6. Ward E, DeSantis C, Robbins A, et al.: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64 (2): 83-103, 2014 Mar-Apr. [PUBMED Abstract]
  7. Gatta G, Capocaccia R, Botta L, et al.: Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Lancet Oncol 18 (8): 1022-1039, 2017. [PUBMED Abstract]
  8. DeSantis CE, Kramer JL, Jemal A: The burden of rare cancers in the United States. CA Cancer J Clin 67 (4): 261-272, 2017. [PUBMED Abstract]
  9. Ferrari A, Brecht IB, Gatta G, et al.: Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors. Eur J Cancer 110: 120-126, 2019. [PUBMED Abstract]
  10. Pappo AS, Krailo M, Chen Z, et al.: Infrequent tumor initiative of the Children's Oncology Group: initial lessons learned and their impact on future plans. J Clin Oncol 28 (33): 5011-6, 2010. [PUBMED Abstract]

Childhood Breast Cancer

Incidence, Histological Types, and Prognosis

Breast cancer has been reported in both males and females younger than 21 years.[1-5]; [6][Level of evidence C1]

A review of the Surveillance, Epidemiology, and End Results (SEER) Program database of the National Cancer Institute shows that 75 cases of malignant breast tumors in females aged 19 years or younger were identified from 1973 to 2004.[7]

  • Fifteen percent of these patients had in situ disease, and 85% of patients had invasive disease.
  • Fifty-five percent of the tumors were carcinomas, and 45% of the tumors were sarcomas, most of which were phyllodes tumors.
  • Only three patients in the carcinoma group presented with metastatic disease, while 11 patients (27%) had regionally advanced disease. All patients with sarcomas presented with localized disease.
  • Of the carcinoma patients, 85% underwent surgical resection, and 10% received adjuvant radiation therapy.
  • Of the sarcoma patients, 97% had surgical resection, and 9% received radiation therapy.
  • The 5- and 10-year survival rates for patients with sarcomatous tumors were both 90%.
  • For patients with carcinomas, the 5-year survival rate was 63%, and the 10-year survival rate was 54%.

A National Cancer Database report described 181 cases of breast malignancies in patients aged 21 years and younger.[4]

  • Sixty-five percent of patients had invasive carcinoma, and the remaining patients had sarcoma or malignant phyllodes.
  • Pediatric patients were more likely to have an undifferentiated malignancy, more advanced disease at presentation, and more variable management.
  • Outcomes in children and adult patients were similar.

A subsequent report from the SEER database (1973–2009) discovered 91 girls aged 10 to 20 years with breast cancer.[6][Level of evidence C1]

  • These cancers were predominantly carcinomas (57% invasive, 5.5% in situ) and sarcomas (37%, mostly phyllodes tumors).
  • The mortality rate was 46.6% for patients with regional disease and 18.7% for patients with localized disease.
  • The mortality rates for the patients in this study were higher than the rates for premenopausal and postmenopausal women, although the sample size was small.

While rare, breast cancer in males has also been described. In a review of the National Cancer Database, 677 male adolescent and young adult (AYA) patients were diagnosed with breast cancer between 1998 and 2010.[3]

  • Most of these patients (82%) had invasive disease.
  • Age younger than 25 years and absence of nodal evaluation at the time of surgery were associated with worse outcomes.

Breast tumors may also occur as metastatic deposits from leukemia, rhabdomyosarcoma, other sarcomas, or lymphoma (particularly in patients who are infected with HIV).

Risk Factors

Risk factors for breast cancer in AYA people include the following:

  1. Previous malignancy. A retrospective review of the American College of Surgeons National Cancer Database from 1998 to 2010 identified 106,771 patients aged 15 to 39 years with breast cancer.[8] Of these patients, 6,241 (5.8%) had experienced a previous histologically distinct malignancy. Patients with breast cancer as a subsequent neoplasm had a significantly decreased 3-year overall survival rate, compared with patients with breast cancer as a primary malignancy (79% vs. 88.5%, P < .001). Subsequent neoplasm status was identified as an independent risk factor for increased mortality (hazard ratio, 1.58; 95% confidence interval, 1.41–1.77).
  2. Chest irradiation. There is an increased lifetime risk of breast cancer in female survivors of Hodgkin lymphoma who were treated with radiation to the chest area. However, breast cancer is also seen in patients who were treated with chest irradiation for any cancer.[9-13][Level of evidence A2] Carcinomas are more frequent than sarcomas in these patients.

    Mammography with adjunctive breast magnetic resonance imaging (MRI) starts at age 25 years or 8 years after exposure to radiation therapy (whichever came last). For more information about secondary breast cancers, see Late Effects of Treatment for Childhood Cancer.

Genetic Factors

Homologous recombination deficiency (HRD) is a prevalent phenotype of breast cancer in AYA patients (aged 15–39 years). HRD influences the efficacy of PARP inhibitor–based therapy and platinum agent–based therapy.[14,15]

An analysis of 46 Japanese AYA patients with breast cancer and two existing breast cancer cohorts of U.S. and European patients identified an HRD-high phenotype that was associated with germline BRCA1 and BRCA2 pathogenic variants, somatic TP53 variants, triple-negative subtype, and higher tumor grade.[14] A model based on three of these factors, excluding germline BRCA1 and BRCA2 pathogenic variants, yielded high predictive power of death in cases from these two cohorts without germline BRCA1 or BRCA2 pathogenic variants; the area under the receiver operating characteristic curve was 0.92 and 0.90, respectively.

Treatment of Breast Cancer in Adolescents and Young Adults (AYA)

Breast cancer is the most frequently diagnosed cancer among AYA women aged 15 to 39 years, accounting for about 14% of all AYA cancer diagnoses.[16] Breast cancer in this age group has a more aggressive course and worse outcome than in older women. Expression of hormone receptors for estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) on breast cancer in the AYA group is also different from that in older women and correlates with a worse prognosis.[8,17]

In a review of data from the National Cancer Database, AYA patients (aged 15–39 years) had a higher incidence of triple-negative breast cancer (TNBC) or HER2-positive (HER2+) cancer than did adult patients (TNBC: 21.2% vs. 13.8%, respectively; HER2+: 26.0% vs. 18.6%, respectively; both P < .001). In addition, patients aged 15 to 29 years had more advanced disease and TNBC or HER2+ disease than did patients aged 30 to 39 years.[18][Level of evidence C1]

Treatment of AYA patients is similar to that of older women. However, unique aspects of management include attention to genetic implications (i.e., familial breast cancer syndromes) and fertility.[19,20]

For more information, see Breast Cancer Treatment and Genetics of Breast and Gynecologic Cancers.

Treatment Options Under Clinical Evaluation for Childhood and AYA Breast Cancer

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

  • NCT05879926 (Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression Plus Hormonal Therapy in Premenopausal Estrogen Receptor (ER)–Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning [OFSET Trial]): This phase III trial will determine whether adjuvant chemotherapy added to ovarian function suppression and endocrine therapy improves invasive breast cancer–free survival among premenopausal, early-stage breast cancer patients (aged 18 years and older) with ER-positive, HER2-negative tumors and a 21-gene recurrence score between 16 and 25 (for pN0 patients) or 0 and 25 (for pN1 patients).
References
  1. Rivera-Hueto F, Hevia-Vázquez A, Utrilla-Alcolea JC, et al.: Long-term prognosis of teenagers with breast cancer. Int J Surg Pathol 10 (4): 273-9, 2002. [PUBMED Abstract]
  2. Costa NM, Rodrigues H, Pereira H, et al.: Secretory breast carcinoma--case report and review of the medical literature. Breast 13 (4): 353-5, 2004. [PUBMED Abstract]
  3. Flaherty DC, Bawa R, Burton C, et al.: Breast Cancer in Male Adolescents and Young Adults. Ann Surg Oncol 24 (1): 84-90, 2017. [PUBMED Abstract]
  4. Richards MK, Goldin AB, Beierle EA, et al.: Breast Malignancies in Children: Presentation, Management, and Survival. Ann Surg Oncol 24 (6): 1482-1491, 2017. [PUBMED Abstract]
  5. Veiga LH, Curtis RE, Morton LM, et al.: Association of Breast Cancer Risk After Childhood Cancer With Radiation Dose to the Breast and Anthracycline Use: A Report From the Childhood Cancer Survivor Study. JAMA Pediatr 173 (12): 1171-1179, 2019. [PUBMED Abstract]
  6. Murthy V, Pawar S, Chamberlain RS: Disease Severity, Presentation, and Clinical Outcomes Among Adolescents With Malignant Breast Neoplasms: A 20-Year Population-Based Outcomes Study From the SEER Database (1973-2009). Clin Breast Cancer 17 (5): 392-398, 2017. [PUBMED Abstract]
  7. Gutierrez JC, Housri N, Koniaris LG, et al.: Malignant breast cancer in children: a review of 75 patients. J Surg Res 147 (2): 182-8, 2008. [PUBMED Abstract]
  8. Sadler C, Goldfarb M: Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer 121 (8): 1295-302, 2015. [PUBMED Abstract]
  9. Kaste SC, Hudson MM, Jones DJ, et al.: Breast masses in women treated for childhood cancer: incidence and screening guidelines. Cancer 82 (4): 784-92, 1998. [PUBMED Abstract]
  10. Metayer C, Lynch CF, Clarke EA, et al.: Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18 (12): 2435-43, 2000. [PUBMED Abstract]
  11. Swerdlow AJ, Barber JA, Hudson GV, et al.: Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 18 (3): 498-509, 2000. [PUBMED Abstract]
  12. van Leeuwen FE, Klokman WJ, Veer MB, et al.: Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 18 (3): 487-97, 2000. [PUBMED Abstract]
  13. Henderson TO, Amsterdam A, Bhatia S, et al.: Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med 152 (7): 444-55; W144-54, 2010. [PUBMED Abstract]
  14. Watanabe T, Honda T, Totsuka H, et al.: Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults. Breast Cancer Res Treat 182 (2): 491-502, 2020. [PUBMED Abstract]
  15. Kataoka A, Tokunaga E, Masuda N, et al.: Clinicopathological features of young patients (<35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study. Breast Cancer 21 (6): 643-50, 2014. [PUBMED Abstract]
  16. Keegan TH, DeRouen MC, Press DJ, et al.: Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res 14 (2): R55, 2012. [PUBMED Abstract]
  17. Anders CK, Hsu DS, Broadwater G, et al.: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26 (20): 3324-30, 2008. [PUBMED Abstract]
  18. Murphy BL, Day CN, Hoskin TL, et al.: Adolescents and Young Adults with Breast Cancer have More Aggressive Disease and Treatment Than Patients in Their Forties. Ann Surg Oncol 26 (12): 3920-3930, 2019. [PUBMED Abstract]
  19. Gabriel CA, Domchek SM: Breast cancer in young women. Breast Cancer Res 12 (5): 212, 2010. [PUBMED Abstract]
  20. Tichy JR, Lim E, Anders CK: Breast cancer in adolescents and young adults: a review with a focus on biology. J Natl Compr Canc Netw 11 (9): 1060-9, 2013. [PUBMED Abstract]

Latest Updates to This Summary (09/11/2024)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

This summary was comprehensively reviewed.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® Cancer Information for Health Professionals pages.

About This PDQ Summary

Purpose of This Summary

This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood breast tumors. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.

Reviewers and Updates

This summary is reviewed regularly and updated as necessary by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).

Board members review recently published articles each month to determine whether an article should:

  • be discussed at a meeting,
  • be cited with text, or
  • replace or update an existing article that is already cited.

Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.

The lead reviewers for Childhood Breast Tumors Treatment are:

  • Denise Adams, MD (Children's Hospital Boston)
  • Karen J. Marcus, MD, FACR (Dana-Farber Cancer Institute/Boston Children's Hospital)
  • William H. Meyer, MD
  • Paul A. Meyers, MD (Memorial Sloan-Kettering Cancer Center)
  • Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)
  • Alberto S. Pappo, MD (St. Jude Children's Research Hospital)
  • Arthur Kim Ritchey, MD (Children's Hospital of Pittsburgh of UPMC)
  • Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)
  • Stephen J. Shochat, MD (St. Jude Children's Research Hospital)

Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's Email Us. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.

Levels of Evidence

Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a formal evidence ranking system in developing its level-of-evidence designations.

Permission to Use This Summary

PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”

The preferred citation for this PDQ summary is:

PDQ® Pediatric Treatment Editorial Board. PDQ Childhood Breast Tumors Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: https://www.cancer.gov/types/breast/hp/child-breast-treatment-pdq. Accessed <MM/DD/YYYY>. [PMID: 31593386]

Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in Visuals Online, a collection of over 2,000 scientific images.

Disclaimer

Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the Managing Cancer Care page.

Contact Us

More information about contacting us or receiving help with the Cancer.gov website can be found on our Contact Us for Help page. Questions can also be submitted to Cancer.gov through the website’s Email Us.

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Childhood Breast Tumors Treatment (PDQ®)–Health Professional Version was originally published by the National Cancer Institute.”

Email